The Journal of Experimental Medicine
Rockland Immunochemicals for Research
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 157K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haurum, J. S.
Right arrow Articles by Elliott, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haurum, J. S.
Right arrow Articles by Elliott, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
J. Exp. Med., Volume 190, Number 1, July 5, 1999 145-150
Copyright © 1999 by The Rockefeller University Press.

Presentation of Cytosolic Glycosylated Peptides by Human Class I Major Histocompatibility Complex Molecules In Vivo

John S. Hauruma,c, Ingelise Bjerring Høierc, Gemma Arsequelld, Anne Neisige, Gregorio Valenciad, Jesper Zeuthenc, Jacques Neefjese, and Tim Elliottb
a From the Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, England
b From the Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, England
c Institute of Cancer Biology, Danish Cancer Society, 2100 Copenhagen, Denmark
d Unit of Glycoconjugate Chemistry, CID-CSIC, E08034 Barcelona, Spain
e Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

Correspondence to: John S. Haurum

Antigens presented by class I major histocompatibility complex (MHC) molecules for recognition by cytotoxic T lymphocytes consist of 8–10-amino-acid-long cytosolic peptides. It is not known whether posttranslationally modified peptides are also presented by class I MHC molecules in vivo. Many different posttranslational modifications occur on cytoplasmic proteins, including a cytosolic O-ß-linked glycosylation of serine and threonine residues with N-acetylglucosamine (GlcNAc). Using synthetic glycopeptides carrying the monosaccharide O-ß-GlcNAc substitution on serine residues, we have shown that glycopeptides bind efficiently to class I MHC molecules and elicit a glycopeptide-specific cytotoxic T lymphocyte response in mice. In this study, we provide evidence that peptides presented by human class I MHC molecules in vivo encompass a small, significant amount of glycopeptides, constituting up to 0.1% of total peptide. Furthermore, we find that carbohydrate structures present on glycopeptides isolated from class I MHC molecules are dominated by the cytosolic O-ß-GlcNAc substitution, and synthetic peptides carrying this substitution are efficiently transported by TAP (transporter associated with antigen presentation) into the endoplasmic reticulum. Thus, in addition to unmodified peptides, posttranslationally modified cytosolic peptides carrying O-ß-linked GlcNAc can be presented by class I MHC molecules to the immune system.

Key Words: glycopeptides/immunology, class I histocompatibility antigens, posttranslational protein processing, antigen presentation, acetylglucosamine


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS